Varian introduces Ethos therapy – AI-powered cancer care delivery solution

Ethos therapy Varian : Varian, a cancer care technologies developer, has introduced Ethos therapy, an artificial intelligence (AI)-powered personalized cancer care delivery system in radiation oncology, as per the latest medical device news.

Ethos therapy, designed to deliver adaptive treatment in a typical 15-minute timeslot, will target the tumor, reduce dose to healthy tissue and improve overall results.

The adaptive cancer care delivery system uses multimodality images (MR, PET, CT), and daily iterative CBCT images to help clinicians assess anatomical changes and to make more informed adaptive treatment decisions.

Chris Toth – president, Varian Oncology Systems, commenting on the Ethos therapy, said: “Adaptive therapy is the future of personalized radiation therapy.

“Beginning with IMRT we were able to shape dose with more fidelity, and then image guided radiation therapy (IGRT) allowed us to target with more precision.

“Ethos therapy, powered by AI, will allow us to adapt and personalize dose to every patient, every day in a typical treatment timeslot.”

Varian introduces new AI-powered cancer care delivery solution called Ethos therapy. Photo courtesy of Varian Medical Systems, Inc.

In April 2019, Varian formed the Adaptive Intelligence Consortium that includes clinicians and scientists from across the globe to conduct clinical trials and develop clinical protocols for its new AI-based cancer care delivery system.

Commenting on Ethos therapy Varian, Poul Geertsen – head of Radiotherapy, Department of Oncology, Herlev and Gentofte Hospital said: “Ethos therapy will enable our physicians to better visualize the changes in a patient’s anatomy and quickly adapt the therapy accordingly to help provide better treatments to patients.

“We have already delivered the first Ethos therapy treatment and our clinical staff was impressed by the capabilities and the ability to deliver this advanced treatment in a typical timeslot.”

Ethos therapy Varian has secured CE mark, while its 510(k) premarket submission made to the US FDA is pending.